Sanofi (SNY) Operating Expenses (2009 - 2026)

Sanofi has disclosed Operating Expenses across 18 years of filings, most recently posting -$4.8 billion for Q1 2026.

• Operating Expenses for Q1 2026 came in at -$4.8 billion, down 12.52% year-over-year; the trailing twelve-month figure through Mar 2026 was -$44.2 billion (down 44.7% YoY), and the FY2025 annual result was $21.6 billion, up 12.27% from the prior year.
• Operating Expenses came in at -$4.8 billion for Q1 2026 at Sanofi, up from -$20.2 billion in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of -$4.1 billion in Q1 2024 to a low of -$20.2 billion in Q4 2025.
• The 5-year median for Operating Expenses is -$4.6 billion (2023), against an average of -$8.2 billion.
• Across the five-year window, Operating Expenses grew 9.29% in 2024 and plunged 225.84% in 2025, its largest moves.
• Sanofi's Operating Expenses stood at -$17.5 billion in 2022, then advanced by 5.32% to -$16.6 billion in 2023, then dropped by 6.63% to -$17.7 billion in 2024, then fell by 14.24% to -$20.2 billion in 2025, then soared by 76.43% to -$4.8 billion in 2026.
• The last three Operating Expenses figures came in at -$4.8 billion (Q1 2026), -$20.2 billion (Q4 2025), and -$14.4 billion (Q3 2025), per Business Quant data.